DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Anacetrapib
Anacetrapib
Prevention of Coronary Heart Disease
1 CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on A
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
Articles Article: Non-Statin Treatments for Managing LDL Cholesterol and Their Outcomes Download
2 12/ 35 74Al
High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm
Stembook 2018.Pdf
Study Protocol 1002-039 Amendment 1, 05 March 2017
Ep 2838891 B1
Product List
Lipidomic Biomarkers for Atherosclerosis and Cardiovascular Disease
HPS 3 / TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification)
Anacetrapib for the Treatment of Dyslipidemia
CT-16427 REPATHA REEVAL PIC AVIS3 CT16427.Pdf
Prevention of Murine Atherosclerosis with Bempedoic Acid
Top View
Novel HDL Targeted Therapies
Anacetrapib Reduces Progression of Atherosclerosis, Mainly by Reducing Non-HDL- Cholesterol, Improves Lesion Stability and Adds
Annual Report 2013
ACC 2019 – Anacetrapib Analysis Throws Doubt on Dalcor Play
Pharmacologic Therapies
Treatment of Dyslipidaemia in Children
Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification
Anacetrapib, a New CETP Inhibitor: the New Tool for the Management of Dyslipidemias?
ESC/EAS Guidelines for the Management of Dyslipidemias
ACC 2019 Preview – Amarin and Esperion Look for an Edge
Statins: Adverse Reactions, Oxidative Stress and Metabolic Interactions
Novel Therapies for HDL
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: a Systematic Review and Meta-Analysis
Anacetrapib Reduces Progression of Atherosclerosis, Mainly by Reducing Non-HDL- Cholesterol, Improves Lesion Stability and Adds
Current Issues and Controversies in Lipid Management in Women
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients with Coronary Heart Disease
Anacetrapib Reduces (V)LDL Cholesterol by Inhibition of CETP Activity and Reduction of Plasma PCSK9
Wo 2010/005480 A2